Filament Health
Phase II1 active candidate3 trials
2 shared indicationsPhase II peer2 shared regulatorssimilar active pipeline size
Back to StakeholdersProgramme tracker View landscape
Lead program: Phase II
Categories
1 domain / 2 areas / 1 specialization
Mydecine InnovationsNEO: MYCO
Data updated
2 Drug Candidates
Canadian biotech using AI-assisted drug discovery at the University of Alberta to develop novel psilocybin and MDMA analogues for mental health and addiction treatment. Pipeline compounds MYCO-003 through MYCO-007 represent a library of psychedelic-inspired molecules at preclinical stage.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 2
- Active programmes
- 3
- Lead stage
- Phase II
- Forecast coverage
- 3 of 3
All tracked candidates active
All tracked programmes active
Multiple active stages
3 active programmes with forecast fields
Latest sourced update
Psychedelic Alpha - Psychedelic Drug Development Tracker
Jun 26, 2026 - industry-media - Psychedelic Alpha - MYCO-001
Next known catalyst
Phase II topline
Timing not specified - MYCO-001 / MYCO-001 Phase 2b Programme (Smoking Cessation) - Confidence: 55%
6 sources0 pipeline-linked trials0 pipeline-linked papers1 Phase II1 Preclinical
Development Programmes
2MYCO-001
PsilocybinPhase II
Smoking cessation / PTSD
Programme Tracker
Substance Use Disorders (SUD)
Primary: US (FDA)
Phase IIActive
Forecast
Phase II topline
Phase 2b multi-site placebo-controlled trial; PI: Dr. Matthew Johnson (Johns Hopkins); sites: Hopkins, NYU, UAB; IND filed with FDA
Milestones
Phase II started
CompletedActual: Sep 1, 2022
Phase 2b seamless smoking cessation trial initiated with Johns Hopkins partnership; IRB conditional approval received
Why it matters: MYCO-001 is a 99.9% pure natural-source psilocybin developed in partnership with Johns Hopkins' Dr. Matthew Johnson — the researcher behind the landmark 2022 JAMA Psychiatry smoking cessation study (80% abstinence at 12 months). The Phase 2b replicates this design at multiple sites.
Watch next: Phase 2b 3-month and 6-month abstinence primary endpoint results
Recorded Events
Sep 1, 2022: Phase II started
PTSD
Primary: UK (MHRA)
Phase IIActive
Forecast
Phase II topline
Phase 2a in veteran PTSD; partnership with Combat Stress (UK) and King's College London; PI: Dr. Rakesh Jetly
Milestones
Phase II started
CompletedActual: Jan 24, 2022
Partnership with Combat Stress and King's College London announced for veteran PTSD trial
Why it matters: Dr. Rakesh Jetly is the leading clinical researcher for psilocybin PTSD trials in veterans. Combat Stress is the UK's leading veteran mental health charity. This partnership brings credibility and access to a high-burden, treatment-resistant PTSD population.
Watch next: Phase 2a results in veteran PTSD cohort
Recorded Events
Jan 24, 2022: Phase II started
Evidence Links
Mydecine Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Trial
Press release - GlobeNewswire / Mydecine - Sep 7, 2021 - Verified
Mydecine announced a planned placebo-controlled Phase 2/3 MYCO-001 smoking cessation study with Johns Hopkins; no current registry match was found in June 2026 checks.
Mydecine Provides Company Update on Clinical Trials and Drug Development
Press release - GlobeNewswire / Mydecine - Dec 9, 2021 - Verified
Company update describes MYCO-001 smoking cessation and PTSD Phase 2 plans; no recent 2025-2026 development update was found in this pass.
Psychedelic Alpha - Psychedelic Drug Development Tracker
industry-media - Psychedelic Alpha - Jun 26, 2026 - Verified
Industry tracker continues to list MYCO-001 in clinical-stage psychedelic drug development, but current primary-source progress remains thin.
MYCO-004
Preclinical
Substance use disorder / smoking cessation
Programme Tracker
Substance Use Disorders (SUD)
Primary: US (FDA)
Pre-clinicalActive
MYCO-004 remains supported mainly by 2021 Mydecine disclosures as a patch-delivered tryptamine for SUD/smoking cessation. Mydecine changed its public company name to Noveris Health Sciences in February 2026; no recent MYCO-004 clinical-start confirmation was found.
Milestones
Pre-clinical completed
In progressWhy it matters: MYCO-004 is a transdermal tryptamine — distinct from MYCO-001's oral psilocybin. Patch delivery could enable controlled, slow-release dosing (potentially sub-perceptual) without the 4–6 hour oral psychedelic session, expanding access to patients unwilling or unable to undergo full psychedelic sessions.
Watch next: Preclinical PK/PD data and indication selection for IND
Evidence Links
Mydecine Announces Four Lead Novel Drug Candidates
Press release - GlobeNewswire / Mydecine - Apr 7, 2021 - Verified
Announcement identifies MYCO-004 as a patch-delivered tryptamine compound with short duration and precision dosing.
Mydecine Selects Substance Use Disorder and Smoking Cessation for MYCO-004
Press release - FirstWord Pharma / Mydecine - Jun 1, 2021 - Verified
Announcement supports substance-use disorder and smoking-cessation positioning for MYCO-004.
CSE Bulletin - Mydecine Name and Symbol Change
exchange-notice - Canadian Securities Exchange / Newsfile - Feb 2, 2026 - Verified
CSE bulletin records Mydecine Innovations Group name change to Noveris Health Sciences, useful for current company tracking.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
Reconnect Labs
Phase II3 active candidates2 trials
2 shared indicationsPhase II peersame regulator: US FDAsimilar active pipeline size
Otsuka Pharmaceutical
Phase III2 active candidates
shared compound: Psilocybinsame indication: PTSD2 shared regulatorssimilar active pipeline size
Apex Labs
Phase II2 active candidates1 trial
shared compound: Psilocybinsame indication: PTSDPhase II peersimilar active pipeline size
Quick Facts
- Type
- Public Biotech
- Ticker
- NEO: MYCO
- Lead Stage
- Phase II
- Website
- Visit